CryoPort Inc (CYRX)
NASDAQ:CYRX
Want to see CYRX full AI Analyst Report?
Earnings Data
Report Date
Aug 11, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.19Last Year’s EPS
2.05Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a predominantly positive operational and financial picture: strong 16% revenue growth, double-digit expansion across services and products, record clinical trial support, product innovation (Fusion 800), and a $2.2M improvement in adjusted EBITDA. Management raised full-year revenue guidance and expects positive adjusted EBITDA in H2 2026. Key near-term cautions include a conservative guide raise despite a beat, the company not yet at positive adjusted EBITDA, product-margin mix variability, and multi-quarter ramps for IntegraCell and new facilities that limit 2026 contribution. Overall the positives (top-line growth, pipeline depth, milestones, margin improvement initiatives, and operational expansions) materially outweigh the identified lowlights.Company Guidance
Top-Line Growth
Revenue of $47.8 million in Q1 2026, up 16% year over year, representing a strong start to the year and prompting an upward revision to full-year revenue guidance of $192 million to $196 million.
Commercial Cell & Gene Therapy Momentum
Revenue supporting commercial cell and gene therapies grew 26% year over year to $9.1 million, and the company now supports 21 commercial therapies following an accelerated FDA approval for a client (Crislotti).
Clinical Trial Revenue and Pipeline Depth
Clinical trial–related revenue increased 18% year over year to $12.9 million. Cryoport supports a record 766 global clinical trials (net +55 YoY) with 91 trials in Phase III, providing a large, maturing base for future commercial conversions.
Segment Strength — Life Sciences Services
Life Sciences Services revenue grew 18% year over year, driven by biostorage/bioservices growth of 21%, reflecting increased adoption of the integrated services portfolio.
Segment Strength — Life Sciences Products (MVE)
Life Sciences Products revenue grew 15% year over year, driven by global demand for MVE cryogenic systems and new product introductions (e.g., Fusion 800 series) that open previously inaccessible markets.
Improvement in Adjusted EBITDA
Adjusted EBITDA from continuing operations improved by $2.2 million year over year, moving the company meaningfully along its pathway to profitability; Q1 adjusted EBITDA was near breakeven (negative $0.6 million).
IntegraCell Operational Milestone
IntegraCell shipped its first cryopreserved clinical trial patient materials from both Houston and Liège facilities, marking initial commercial service execution and validating the offering as a future revenue and margin driver.
Strategic Facility and Capacity Expansion
Paris site operational for biologics (since November) with bioservices coming in Q3; new Santa Ana, CA facility (approx. 94,000 sq ft) consolidating operations and expanding West Coast capacity—both expected to ramp in the second half of 2026 and contribute more in 2027.
Adoption of Digital and AI Initiatives
Company advancing digitization and enterprise-approved generative AI initiatives aimed at automating repetitive tasks, improving real-time data analysis, managing risk, and increasing operational efficiency with tangible early benefits.
Positive Market Tailwinds and Funding
Industry funding improvements (strength noted in April) and maturation of trials (Phase II and Phase III increases) are supporting greater client activity and potential acceleration of commercial launches; management expects up to eight additional therapy approvals in 2026.
CYRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CYRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 03, 2026 | $8.49 | $8.74 | +2.94% |
Nov 04, 2025 | $9.22 | $8.53 | -7.48% |
Aug 05, 2025 | $6.74 | $8.75 | +29.82% |
May 07, 2025 | $5.66 | $6.98 | +23.32% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does CryoPort Inc (CYRX) report earnings?
CryoPort Inc (CYRX) is schdueled to report earning on Aug 11, 2026, After Close (Confirmed).
What is CryoPort Inc (CYRX) earnings time?
CryoPort Inc (CYRX) earnings time is at Aug 11, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CYRX EPS forecast?
CYRX EPS forecast for the fiscal quarter 2026 (Q2) is -0.19.